相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
1616413-96-7
- 规格:
1 mg/5 mg/10 mg/25 mg/50 mg
| 规格: | 1 mg | 产品价格: | ¥516.0 |
|---|---|---|---|
| 规格: | 5 mg | 产品价格: | ¥1185.0 |
| 规格: | 10 mg | 产品价格: | ¥1788.0 |
| 规格: | 25 mg | 产品价格: | ¥3513.0 |
| 规格: | 50 mg | 产品价格: | ¥5013.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
UCB9608
CAS No. : 1616413-96-7
MCE 国际站:UCB9608
产品活性:UCB9608 是一种有效、选择性、可口服的 PI4KIIIβ 抑制剂,IC50 值为 11 nM,对其选择性高于 PI3KC2 α,β 和 γ。UCB9608 增加了代谢稳定性,表现出良好的药代动力学特征,可作为免疫抑制剂。
研究领域:PI3K/Akt/mTOR
作用靶点:PI4K
In Vitro: UCB9608 is a potent, selective and orally active PI4KIIIβ inhibitor, with an IC50 of 11 nM. UCB9608 is selective for PI4KIIIβ over PI3KC2 α, β, and γ lipid kinases.
UCB9608 inhibits human mixed lymphocyte reaction, the IC50 is 37 nM.
相关产品:Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Anti-Aging Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Orally Active Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Glucose Metabolism Compound Library | Targeted Diversity Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Highly Selective Inhibitors Library | PIK-93 | BF738735 | PI-273 | PI4KIIIbeta-IN-10 | T-00127_HEV1 | BQR-695 | PI4KIIIbeta-IN-9 | GSK-A1 | PI4KIII beta inhibitor 3 | MMV390048 | KDU691 | BI-1622 | GSK-F1 | KDU731 | UCT943 | AL-9 | CHMFL-PI4K-127 | EDI048 | MI 14 | MIPS-21335 | PI4K-IN-1 | PI4KIIIbeta-IN-11
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验II 期,实验者为接受脐带血(UCB)移植的白血病或淋巴瘤的患者。起初,Prohema 之所以会被在斑马鱼上被筛选出来是因为它会增加或减少造血干细胞(HSC)的数量。我们用自动原位杂交法给胚胎主动脉-性腺-中肾区的 HSC 染色,进而筛选出提高或降低 HSC 数量的药物。Prohema 的治疗潜力最早在成年斑马鱼被展示,它增强了斑马鱼在亚致死照射后骨髓恢复的速率。在小鼠中,全骨髓暴露于 Prohema 的体外能形成更多脾集落形成单位。同样,Prohema 处理的全骨髓能更有效地重建造血系统,并制造
技术资料暂无技术资料 索取技术资料

















